Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Kelleher, Nicholas; Gallardo, David; González‐Campos, José; Hernández‐Rivas, Jesús María; Montesinos, Pau; Sarrà, Josep; Gil, Cristina; Barba, Pere; Brunet, Salut; Bernal, Teresa; Martínez, M. Labalde; Abella, Eugènia; Bermúdez, Arantxa; Sánchez-Delgado, M.; Cladera, Antònia; Gayoso, Jorge; Calbacho, M.; Ribera, Josep‐Marǐa

doi:10.3109/10428194.2015.1040013

Cited by 16 publications

(20 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intriguingly, in addition to the expected high incidence of MLL gene rearrangement, Philadelphia chromosome (Ph) [t(9;22)(q34.1;q11.2) resulting inBCR-ABL1 fusion] was frequently observed among these t-ALL cases. In fact, Ph chromosome was the most common cytogenetic finding in our previous t-ALL case series (11 out of 28 cases) as well as in other reports of t-ALL [1][2][3][4][5]. The vast majority of reported cases of therapy-related Ph1 AL have precursor B-cell phenotype although rare cases with T-cell ALL and acute myeloid leukemia (AML) phenotype have been reported [6,7].…”

Section: Philadelphia Chromosome As a Recurrent Event Among Therapy-rsupporting

confidence: 52%

“…To the Editor: The majority of therapy-related acute leukemias (t-AL) have a myeloid phenotype. However, therapy-related acute lymphoblastic leukemia (t-ALL) is increasingly being recognized as a subset of t-AL [1][2][3][4][5]. Intriguingly, in addition to the expected high incidence of MLL gene rearrangement, Philadelphia chromosome (Ph) [t(9;22)(q34.1;q11.2) resulting inBCR-ABL1 fusion] was frequently observed among these t-ALL cases.…”

Section: Philadelphia Chromosome As a Recurrent Event Among Therapy-rmentioning

confidence: 99%

“…However, establishing the diagnosis of tissueinvasive CMV disease is not trivial due to the following reasons: (i) poor correlation between presence/quantitative level of CMV DNAemia/antigenemia and CMV disease [3], (ii) invasiveness of tissue-directed diagnostic procedures, (iii) viral shedding without true tissue involvement, and (iv) frequent coexistence of graft-versus-host disease (GVHD) [4], which can alter and/or mimic the classic morphology of CMV disease. Currently, diagnosis is based on (i) CMV DNAemia/antigenemia, (ii) morphological findings of CMV disease on hematoxylin and eosin (H&E)-stained specimens, and (iii) immunohistochemistry (IHC) using CMV antibody [5]. However, a conclusive diagnostic modality when H&E-and/or IHC-based findings are equivocal or inconsistent is not available and toxic anti-CMV therapy can be detrimental in equivocal cases without tissue-invasive disease.…”

Section: Tissue Polymerase Chain Reaction For the Diagnosis Of Cytomementioning

confidence: 99%

See 2 more Smart Citations

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

et al. 2017

View full text Add to dashboard Cite

Section: Philadelphia Chromosome As a Recurrent Event Among Therapy-rsupporting

confidence: 52%

Section: Philadelphia Chromosome As a Recurrent Event Among Therapy-rmentioning

confidence: 99%

Section: Tissue Polymerase Chain Reaction For the Diagnosis Of Cytomementioning

confidence: 99%

See 1 more Smart Citation

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

et al. 2017

View full text Add to dashboard Cite

“…4 Because of the rarity of this newly recognized subgroup, our knowledge is limited to individual case series and registry data. [4][5][6][7][8][9][10][11][12][13] However, most of these individual reports did not include critical genomic data, and the definition of t-ALL has varied; these have created a debate over the existence of a distinct t-ALL entity.…”

Section: Introductionmentioning

confidence: 99%

“…MDS-like cytogenetic abnormalities included deletions of chromosomes5,7,11,13,17, and 20, as well as trisomy 8.…”

mentioning

confidence: 99%

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

et al. 2019

View full text Add to dashboard Cite

Therapy-related ALL is a distinct entity associated with poor-risk cytogenetics and inferior survival compared with de novo ALL.• Hematopoietic stem cell transplantation may improve outcomes and should be considered for all eligible patients with therapyrelated ALL.Patients with therapy-related acute lymphoblastic leukemia (t-ALL) represent a small subset of acute lymphoblastic leukemia (ALL) patients who received genotoxic therapy (ie, chemotherapy or radiation) for a prior malignancy. These patients should be distinguished from patients with de novo ALL (dn-ALL) and ALL patients who have a history of prior malignancy but have not received cytotoxic therapies in the past (acute lymphoblastic leukemia with prior malignancy [pm-ALL]). We report a retrospective multi-institutional study of patients with t-ALL (n 5 116), dn-ALL (n 5 100), and pm-ALL (n 5 20) to investigate the impact of prior cytotoxic therapies on clinical outcomes.Compared with patients with pm-ALL, t-ALL patients had a significantly shorter interval between the first malignancy and ALL diagnosis and a higher frequency of poor-risk cytogenetic features, including KMT2A rearrangements and myelodysplastic syndrome-like abnormalities (eg, monosomal karyotype). We observed a variety of mutations among t-ALL patients, with the majority of patients exhibiting mutations that were more common with myeloid malignancies (eg, DNMT3A, RUNX1, ASXL1), whereas others had ALL-type mutations (eg, CDKN2A, IKZF1). Median overall survival was significantly shorter in the t-ALL cohort compared with patients with dn-ALL or pm-ALL. Patients who were eligible for hematopoietic cell transplantation had improved long-term survival. Collectively, our results support t-ALL as a distinct entity based on its biologic and clinical features.

show abstract

Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia

Nampoothiri

Viswabandya

2020

Indian J Hematol Blood Transfus

View full text Add to dashboard Cite

Incidence, clinical and biological characteristics and outcome of secondary acute lymphoblastic leukemia after solid organ or hematologic malignancy

Cited by 16 publications

References 17 publications

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

Philadelphia chromosome as a recurrent event among therapy‐related acute leukemia

Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes

Allogeneic Hematopoietic Stem Cell Transplantation in Therapy Related Acute Leukemia

Contact Info

Product

Resources

About